Trade AlloVir, Inc. - ALVR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Allovir Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.12 |
Open* | 2.1 |
1-Year Change* | -73.45% |
Day's Range* | 1.96 - 2.1 |
52 wk Range | 2.42-10.29 |
Average Volume (10 days) | 491.15K |
Average Volume (3 months) | 18.39M |
Market Cap | 325.66M |
P/E Ratio | -100.00K |
Shares Outstanding | 113.87M |
Revenue | N/A |
EPS | -1.83 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Nov 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 2, 2023 | 1.98 | -0.13 | -6.16% | 2.11 | 2.11 | 1.96 |
Sep 29, 2023 | 2.12 | -0.04 | -1.85% | 2.16 | 2.24 | 2.11 |
Sep 28, 2023 | 2.19 | 0.00 | 0.00% | 2.19 | 2.21 | 2.08 |
Sep 27, 2023 | 2.19 | -0.06 | -2.67% | 2.25 | 2.34 | 2.18 |
Sep 26, 2023 | 2.25 | -0.01 | -0.44% | 2.26 | 2.51 | 2.24 |
Sep 25, 2023 | 2.32 | 0.10 | 4.50% | 2.22 | 2.33 | 2.15 |
Sep 22, 2023 | 2.26 | 0.07 | 3.20% | 2.19 | 2.28 | 2.16 |
Sep 21, 2023 | 2.25 | 0.12 | 5.63% | 2.13 | 2.32 | 2.10 |
Sep 20, 2023 | 2.25 | 0.09 | 4.17% | 2.16 | 2.38 | 2.13 |
Sep 19, 2023 | 2.21 | -0.01 | -0.45% | 2.22 | 2.22 | 1.89 |
Sep 18, 2023 | 2.12 | -0.38 | -15.20% | 2.50 | 2.51 | 2.08 |
Sep 15, 2023 | 2.48 | -0.18 | -6.77% | 2.66 | 2.69 | 2.41 |
Sep 14, 2023 | 2.68 | 0.22 | 8.94% | 2.46 | 2.73 | 2.44 |
Sep 13, 2023 | 2.44 | -0.21 | -7.92% | 2.65 | 2.66 | 2.44 |
Sep 12, 2023 | 2.64 | -0.15 | -5.38% | 2.79 | 2.84 | 2.63 |
Sep 11, 2023 | 2.83 | -0.05 | -1.74% | 2.88 | 2.91 | 2.76 |
Sep 8, 2023 | 2.87 | 0.01 | 0.35% | 2.86 | 2.89 | 2.72 |
Sep 7, 2023 | 2.85 | -0.14 | -4.68% | 2.99 | 3.00 | 2.83 |
Sep 6, 2023 | 3.01 | -0.04 | -1.31% | 3.05 | 3.12 | 2.80 |
Sep 5, 2023 | 3.03 | -0.14 | -4.42% | 3.17 | 3.30 | 3.01 |
AlloVir, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, November 1, 2023 | ||
Time (UTC) 12:30 | Country US
| Event Q3 2023 Allovir Inc Earnings Release Q3 2023 Allovir Inc Earnings ReleaseForecast -Previous - |
Tuesday, February 13, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Allovir Inc Earnings Release Q4 2023 Allovir Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0.165 | 1.135 |
Revenue | 0 | 0 | 0.165 | 1.135 | |
Total Operating Expense | 171.202 | 169.818 | 71.309 | 26.866 | 4.731 |
Selling/General/Admin. Expenses, Total | 52.332 | 49.083 | 21.646 | 10.618 | 3.031 |
Research & Development | 118.87 | 120.735 | 49.663 | 16.248 | 1.7 |
Operating Income | -171.202 | -169.818 | -71.309 | -26.701 | -3.596 |
Interest Income (Expense), Net Non-Operating | 1.876 | 1.315 | 1.33 | 2.065 | 0.056 |
Other, Net | 0.351 | -2.452 | 0.195 | 0.797 | 1.11 |
Net Income Before Taxes | -168.975 | -170.955 | -69.784 | -23.839 | -2.43 |
Net Income After Taxes | -168.71 | -171.962 | -69.784 | -23.839 | -2.43 |
Net Income Before Extra. Items | -168.71 | -171.962 | -69.784 | -23.839 | -2.43 |
Net Income | -168.71 | -171.962 | -69.784 | -23.839 | -2.43 |
Total Adjustments to Net Income | -5.726 | ||||
Income Available to Common Excl. Extra. Items | -168.71 | -171.962 | -69.784 | -23.839 | -8.156 |
Income Available to Common Incl. Extra. Items | -168.71 | -171.962 | -69.784 | -23.839 | -8.156 |
Diluted Net Income | -168.71 | -171.962 | -69.784 | -23.839 | -8.156 |
Diluted Weighted Average Shares | 76.6549 | 62.7821 | 61.9313 | 69.1735 | 69.1735 |
Diluted EPS Excluding Extraordinary Items | -2.2009 | -2.73903 | -1.1268 | -0.34463 | -0.11791 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -2.2009 | -2.73903 | -1.1268 | -0.34463 | -0.11791 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 47.304 | 43.231 | 40.434 | 42.95 | 44.624 |
Selling/General/Admin. Expenses, Total | 12.48 | 12.513 | 12.014 | 12.946 | 13.245 |
Research & Development | 34.824 | 30.718 | 28.42 | 30.004 | 31.379 |
Operating Income | -47.304 | -43.231 | -40.434 | -42.95 | -44.624 |
Interest Income (Expense), Net Non-Operating | 1.516 | 1.325 | 0.898 | 0.668 | 0.162 |
Other, Net | 0.521 | 0.723 | 0.985 | 0.21 | -0.027 |
Net Income Before Taxes | -45.267 | -41.183 | -38.551 | -42.072 | -44.489 |
Net Income After Taxes | -45.267 | -41.183 | -38.136 | -42.072 | -44.639 |
Net Income Before Extra. Items | -45.267 | -41.183 | -38.136 | -42.072 | -44.639 |
Net Income | -45.267 | -41.183 | -38.136 | -42.072 | -44.639 |
Income Available to Common Excl. Extra. Items | -45.267 | -41.183 | -38.136 | -42.072 | -44.639 |
Income Available to Common Incl. Extra. Items | -45.267 | -41.183 | -38.136 | -42.072 | -44.639 |
Diluted Net Income | -45.267 | -41.183 | -38.136 | -42.072 | -44.639 |
Diluted Weighted Average Shares | 94.6258 | 93.3037 | 92.9798 | 84.9488 | 64.4675 |
Diluted EPS Excluding Extraordinary Items | -0.47838 | -0.44139 | -0.41015 | -0.49526 | -0.69243 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.47838 | -0.44139 | -0.41015 | -0.49526 | -0.69243 |
Revenue |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 243.052 | 253.348 | 361.317 | 127.313 | 25.313 |
Cash and Short Term Investments | 233.795 | 248.12 | 356.324 | 126.077 | 22.199 |
Cash & Equivalents | 106.092 | 201.661 | 122.661 | 61.084 | 22.199 |
Short Term Investments | 127.703 | 46.459 | 233.663 | 64.993 | 0 |
Total Receivables, Net | 0.157 | 0.05 | 0.45 | 0.56 | 0.302 |
Accounts Receivable - Trade, Net | 0 | 0.298 | 0.302 | ||
Prepaid Expenses | 9.1 | 5.178 | 4.543 | 0.676 | 0.051 |
Other Current Assets, Total | 0 | 2.761 | |||
Total Assets | 277.079 | 286.594 | 370.821 | 139.422 | 25.319 |
Property/Plant/Equipment, Total - Net | 32.563 | 31.292 | 9.504 | 12.109 | 0 |
Other Long Term Assets, Total | 1.464 | 1.954 | 0 | 0.006 | |
Total Current Liabilities | 24.338 | 37.853 | 12.294 | 9.106 | 3.737 |
Accounts Payable | 3.004 | 8.361 | 0.963 | 0.63 | 0.153 |
Accrued Expenses | 21.15 | 26.743 | 10.759 | 8.23 | 0.674 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.184 | 2.749 | 0.572 | 0.246 | 2.91 |
Total Liabilities | 52.56 | 61.328 | 17.757 | 17.798 | 3.737 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 28.222 | 23.475 | 5.463 | 8.692 | 0 |
Total Equity | 224.519 | 225.266 | 353.064 | 121.624 | 21.582 |
Redeemable Preferred Stock | 0 | 0 | 0 | 173.127 | 52.204 |
Common Stock | 0.009 | 0.007 | 0.007 | 0 | 0 |
Additional Paid-In Capital | 690.753 | 522.479 | 478.272 | 3.748 | 0.858 |
Retained Earnings (Accumulated Deficit) | -465.775 | -297.065 | -125.103 | -55.319 | -31.48 |
Unrealized Gain (Loss) | 0.068 | 0 | |||
Total Liabilities & Shareholders’ Equity | 277.079 | 286.594 | 370.821 | 139.422 | 25.319 |
Total Common Shares Outstanding | 93.0932 | 63.5659 | 61.9313 | 69.1735 | 69.1735 |
Property/Plant/Equipment, Total - Gross | 33.567 | 31.573 | 9.596 | 12.128 | |
Accumulated Depreciation, Total | -1.004 | -0.281 | -0.092 | -0.019 | |
Other Equity, Total | -0.468 | -0.155 | -0.112 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 212.275 | 243.052 | 272.042 | 176.517 | 206.441 |
Cash and Short Term Investments | 202.57 | 233.795 | 264.107 | 172.673 | 201.375 |
Cash & Equivalents | 115.698 | 106.092 | 123.834 | 71.093 | 100.206 |
Short Term Investments | 86.872 | 127.703 | 140.273 | 101.58 | 101.169 |
Total Receivables, Net | 0.244 | 0.157 | 0.261 | 0.091 | 0.172 |
Prepaid Expenses | 9.461 | 9.1 | 7.674 | 3.753 | 4.894 |
Total Assets | 244.044 | 277.079 | 293.698 | 199.995 | 231.09 |
Property/Plant/Equipment, Total - Net | 30.427 | 32.563 | 20.07 | 21.769 | 22.818 |
Total Current Liabilities | 24.959 | 24.338 | 20.719 | 21.588 | 18.639 |
Accounts Payable | 4.134 | 3.004 | 4.889 | 5.518 | 4.473 |
Accrued Expenses | 20.559 | 21.15 | 15.595 | 15.353 | 12.439 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.266 | 0.184 | 0.235 | 0.717 | 1.727 |
Total Liabilities | 50.512 | 52.56 | 40.472 | 41.858 | 39.415 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 25.553 | 28.222 | 19.753 | 20.27 | 20.776 |
Total Equity | 193.532 | 224.519 | 253.226 | 158.137 | 191.675 |
Common Stock | 0.009 | 0.009 | 0.009 | 0.007 | 0.007 |
Additional Paid-In Capital | 700.782 | 690.753 | 681.419 | 544.141 | 532.946 |
Retained Earnings (Accumulated Deficit) | -506.958 | -465.775 | -427.639 | -385.567 | -340.928 |
Unrealized Gain (Loss) | |||||
Total Liabilities & Shareholders’ Equity | 244.044 | 277.079 | 293.698 | 199.995 | 231.09 |
Total Common Shares Outstanding | 93.428 | 93.0932 | 92.6401 | 64.7881 | 64.2641 |
Other Long Term Assets, Total | 1.342 | 1.464 | 1.586 | 1.709 | 1.831 |
Other Equity, Total | -0.301 | -0.468 | -0.563 | -0.444 | -0.35 |
Redeemable Preferred Stock | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -168.71 | -171.962 | -69.784 | -23.839 | -2.43 |
Cash From Operating Activities | -142.052 | -106.319 | -60.811 | -20.155 | 1.943 |
Cash From Operating Activities | 0.723 | 0.189 | 0.073 | 0.019 | 0 |
Non-Cash Items | 42.081 | 46.1 | 9.931 | 2.27 | 0.967 |
Cash Interest Paid | 0 | 0.125 | 0 | ||
Changes in Working Capital | -16.146 | 19.354 | -1.031 | 1.395 | 3.406 |
Cash From Investing Activities | -80.478 | 185.983 | -169.497 | -64.644 | 0 |
Capital Expenditures | 0 | -0.026 | -0.235 | -0.339 | 0 |
Other Investing Cash Flow Items, Total | -80.478 | 186.009 | -169.262 | -64.305 | 0 |
Cash From Financing Activities | 126.961 | 0.232 | 291.975 | 120.923 | 22.872 |
Issuance (Retirement) of Stock, Net | 126.961 | 0.232 | 295.449 | 120.923 | 22.872 |
Net Change in Cash | -95.569 | 79.852 | 61.577 | 36.124 | 24.815 |
Financing Cash Flow Items | 0 | -3.474 | |||
Foreign Exchange Effects | 0 | -0.044 | -0.09 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -41.183 | -168.71 | -130.574 | -88.502 | -43.863 |
Cash From Operating Activities | -32.118 | -142.052 | -110.481 | -75.354 | -46.476 |
Cash From Operating Activities | 0.086 | 0.723 | 0.637 | 0.552 | 0.466 |
Non-Cash Items | 9.761 | 42.081 | 32.901 | 22.187 | 10.923 |
Changes in Working Capital | -0.782 | -16.146 | -13.445 | -9.591 | -14.002 |
Cash From Investing Activities | 41.724 | -80.478 | -94.015 | -55.458 | -54.979 |
Capital Expenditures | 0 | 0 | 0 | 0 | |
Other Investing Cash Flow Items, Total | 41.724 | -80.478 | -94.015 | -55.458 | -54.979 |
Foreign Exchange Effects | 0 | 0 | 0 | 0 | |
Net Change in Cash | 9.606 | -95.569 | -77.827 | -130.568 | -101.455 |
Cash From Financing Activities | 126.961 | 126.669 | 0.244 | 0 | |
Financing Cash Flow Items | 0 | ||||
Issuance (Retirement) of Stock, Net | 126.961 | 126.669 | 0.244 | ||
Cash Taxes Paid | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AlloVir, Inc. Company profile
About Allovir Inc
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). Its LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Allovir Inc revenues was not reported. Net loss increased from $69.8M to $172M. Higher net loss reflects Research and development increase from $46.1M to $100.1M (expense), Stock-based Compensation in SGA increase from $5.9M to $23.3M (expense), Stock-based Compensation in R&D increase from $3.6M to $20.6M (expense).
Industry: | Bio Therapeutic Drugs |
1100 Winter Street
WALTHAM
MASSACHUSETTS 02451
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com